Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19978477 | 0.99 | ALOX5 (0.32) | ALOX5MMP12MMP13KDM4EMEN1 | |
| SCHEMBL19978465 | 0.99 | ALOX5 (0.32) | ALOX5MMP12MMP13KDM4EMEN1 | |
| SCHEMBL19978460 | 0.95 | MMP12 (0.32) | ALOX5MMP12MMP13 | |
| SCHEMBL19978436 | 0.95 | ALOX5 (0.31) | ALOX5MMP12MMP13 | |
| SCHEMBL19978454 | 0.95 | MMP12 (0.32) | ALOX5MMP12MMP13 | |
| SCHEMBL19978481 | 0.92 | AHR (0.32) | KDM4EMEN1MAPTKMT2AAHR | |
| SCHEMBL17827430 | 0.92 | MEN1 (0.36) | ALOX5MMP12MMP13KDM4EMEN1 | |
| SCHEMBL18969066 | 0.91 | AHR (0.32) | MMP12MMP13KDM4EMEN1MAPT | |
| SCHEMBL17827438 | 0.90 | PLA2G2A (0.35) | ALOX5MMP12MMP13KDM4EMEN1 | |
| SCHEMBL23846107 | 0.89 | MMP12 (0.33) | ALOX5MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10411191-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-09-10 | — | — | US | disclosed |
| US-20180083196-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-03-22 | — | — | US | disclosed |
| US-20180083196-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180083196-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNE2 | ALOX5 1947/4885MMP12 4612/4885MMP13 4805/4885 |
| US-10411191-B2 | Condensed cyclic compound and organic light-emitting device including the same | CRY1, CRY2, CCNE2 | ALOX5 1947/4885MMP12 4612/4885MMP13 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.